Disulfiram + Atazanavir

The combination of disulfiram and atazanavir represents an interaction between two distinct medications used in different therapeutic contexts. Disulfiram (Antabuse®) is an FDA-approved medication for treating alcohol dependence, while atazanavir is an antiretroviral medication used in HIV treatment. The search results indicate a significant pharmacokinetic interaction between these drugs. Atazanavir appears to decrease the effectiveness of disulfiram by inhibiting CYP3A4, which is involved in metabolizing disulfiram to its active form that inhibits aldehyde dehydrogenase (ALDH)[1][2]. This interaction could potentially render disulfiram ineffective in treating alcoholism when co-administered with atazanavir[1][2]. ## Pharmacological Interaction Disulfiram works by inhibiting aldehyde dehydrogenase (ALDH), which converts acetaldehyde to acetate during alcohol metabolism. When alcohol is consumed while taking disulfiram, acetaldehyde accumulates, causing unpleasant symptoms like flushing, weakness, nausea, and tachycardia - the "disulfiram-alcohol reaction"[2]. The research indicates that atazanavir co-administration reduced the effect of disulfiram on ALDH activity, likely due to atazanavir's inhibition of CYP3A4[1][2]. This enzyme is responsible for metabolizing disulfiram carbamate to DETC-MeSO, which is the metabolite that inhibits ALDH. By contrast, efavirenz (another antiretroviral) had the opposite effect, increasing disulfiram's inhibition of ALDH[1][2]. ## Clinical Implications For HIV patients with alcohol use disorders, this interaction suggests that atazanavir may not be the optimal antiretroviral choice if disulfiram therapy is being considered[1][2]. The PDR.Net drug summary recommends clinical monitoring for adverse effects when these medications are co-administered, noting that "the plasma concentrations of disulfiram may be elevated when administered concurrently with atazanavir"[4]. This interaction highlights the importance of considering potential drug interactions when treating co-occurring HIV and alcohol use disorders, which are known to complicate HIV treatment and lead to poor outcomes[1][2].